

ACUTE LYMPHOBLASTIC LEUKEMIA ~ STUDY #2

Title: COG AALL1122 (BMS CA180-372): A Phase 2 Multi-Center Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.

Purpose: To find out what the survival rate is when dasatinib is added to a standard chemotherapy. Additional goals of the study are to evaluate the side effects of dasatinib added to standard chemotherapy, to compare the survival rate in this study to that seen with a similar but less potent drug called imatinib when added to this same chemotherapy and other treatments and to monitor the response of your disease to this treatment with disease specific tests (minimal residual disease).

Eligibility: Males and females, age > 1 year (365 days) and < 18 (17 years and 364 days) years at diagnosis. Must have Philadelphia chromosome-positive acute lymphoblastic leukemia.

Principal Investigator: [Joseph M. Wiley, M.D.](#)

Phase: II

For more information, contact: [Stephanie Entrup](#)

Telephone Number: 410-601-8393

Email: sentrup@lifebridgehealth.org